IMTE

Integrated MediaC

Nasdaq / Technology Hardware & Equipment

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

20%

Probability

Target price

$0.80

+48.1% vs current

Most likely

Base case

40%

Probability

Target price

$0.42

-22.2% vs current

B-

Bear case

40%

Probability

Target price

$0.12

-77.8% vs current

AI sentiment snapshot

Latest data as of 2026-05-16

AI commentary

This remains a low-conviction monitoring setup. For the scheduled post-earnings follow-up tied to May 13, 2026, no company earnings release, 6-K, shareholder letter, or IR presentation was confirmed from the company on or around that date; the latest confirmed company financial update checked was the February 10, 2026 Form 6-K containing the interim report, and the next dated company filing checked was the May 1, 2026 AGM notice [#6K-2026-02-10] [#6K-2026-05-01]. Analyst revision, target-change, and consensus-surprise data were unavailable, so the memo should stay event-driven rather than upgrade on thin evidence. The stock’s sub-$1 anchor price on May 15, 2026 versus the June 29, 2026 Nasdaq bid-price deadline keeps sentiment fragile and skewed by listing/financing headlines rather than operating momentum.

RankAlpha Sentiment Codex - 2026-05-16

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-29eventAnnual general meeting on May 29, 2026High impact

The May 1, 2026 Form 6-K set the AGM for May 29, 2026 and said directors will provide an update on completion and audit of outstanding Australian statutory reports, while shareholders also vote on director appointments and an ESOP; any governance, reporting, or capital-structure update could matter because formal disclosure is sparse [#6K-2026-05-01].

2026-06-29eventNasdaq minimum-bid cure deadline on June 29, 2026High impact

IMTE disclosed that Nasdaq gave it until June 29, 2026 to regain the $1.00 minimum bid requirement, with at least 10 consecutive business days above $1.00 needed to cure; failure can push the stock toward delisting, while any cure plan or reverse-split action could drive sharp event volatility [#20F-2026-02-02].

2026-06-30catalystFinancing and going-concern monitoring remains the core near-term watch itemHigh impact

The 2025 Form 20-F said cash and cash equivalents were only $160 at December 31, 2025 and management estimated existing cash would not fund operations into the second half of 2026, making any financing, restructuring, or cost action a high-impact near-term signal [#20F-2026-02-02].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-16 • Updated nightlySource: Internal modelMethodology